Apellis upgraded at BofA on launch trajectory for kidney disease therapy
Source: SeekingAlpha
2026-01-21 12:15:33 ET
More on Apellis Pharmaceuticals
- Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
- Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases
- Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch
Read the full article on Seeking Alpha
For further details see:
Apellis upgraded at BofA on launch trajectory for kidney disease therapy
Novartis AG
NASDAQ: NVS
NVS Trading
-3.4% G/L:
$145.35 Last:
1,290,757 Volume:
$146.92 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
